Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The H5 hemagglutinin (HA) is a major surface glycoprotein of the highly pathogenic H5 subtype of influenza A viruses, such as H5N1. It plays a critical role in the early stages of viral infection by mediating both host cell receptor binding and subsequent membrane fusion. Specifically, the HA1 subunit of the homotrimeric protein binds to sialic acid receptors on host cells, while the highly conserved HA2 subunit undergoes conformational changes at low pH to facilitate the fusion of the viral envelope with the endosomal membrane. Because of its essential role in viral entry, H5 hemagglutinin is a primary target for the development of vaccines, neutralizing monoclonal antibodies, and small-molecule entry inhibitors. Therapeutic agents targeting this protein, such as the broadly neutralizing antibodies diridavumab (CR6261) and MEDI8852 (FI6v3), aim to block viral entry or prevent the conformational changes required for membrane fusion. However, the high plasticity of the hemagglutinin protein, driven by antigenic drift and shift, presents a significant challenge, often leading to the emergence of drug-resistant variants and requiring the development of universal vaccines or therapies targeting highly conserved regions like the stem domain.
Inhibition of viral entry by blocking host cell receptor binding or preventing the conformational changes required for membrane fusion.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Influenza A virus H5 hemagglutinin (H5 HA).